Please login to the form below

Not currently logged in
Email:
Password:

Sanofi-aventis and Glenmark partner

Sanofi-aventis and Glenmark Pharmaceuticals have entered into a licensing agreement for the development of chronic pain treatments

Sanofi-aventis (S-A) and Glenmark Pharmaceuticals have entered into a licensing agreement for the development and commercialisation of new chronic pain treatments.

Indian drug company, Glenmark, will receive $20m initially, and additional payments of as much as $325m linked to development, regulatory and sales milestones. French drug maker, S-A, may also pay royalties on sales of products commercialised under the agreement.

S-A will have exclusive marketing rights in North America, the EU and Japan subject to Glenmark's right to co-promote the products in the US and five Eastern European countries. S-A will also have co-marketing rights in 10 other countries including Brazil, Russia and China. Glenmark will retain exclusive rights in India and other countries.

On the day the news was announced, Glenmark advanced 3.6 per cent to 279.45 rupees at the close of trading – the stock's biggest gain since March 29, 2010.

4th May 2010

Share

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
11 London

The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...

Latest intelligence

The Patient Will See You Now – The Evolution of the Doctor-Patient Relationship
The doctor-patient relationship is an ever changing one that changes as society changes. Technology then helps to drive this change along with a wide number of other factors....
Mind the Gap – Challenging Immunisation Apathy and Misinformation
world, the biggest challenges remain apathy and misinformation. Since a measles vaccine was introduced in the UK in 1968, Public Health England estimates that 20 million measles cases and 4,500...
Towards Better HCP Engagement – An Email Masterclass
6% of HCPs prefer being contacted by email, compared to 17% who favour the second most popular option: direct interaction with reps....